CSV August 16, 2020 through August 16, 2022 All Errata for USP–NF How to use

×

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
    - For example, a search on Aminosalicylic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
    - A search for “Aminosalicylic Acid Tablets” will result in anything that specifically contains “Aminosalicylic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
    - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:**You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication Sort descending	Target Online Fix Publication	Description

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication Sort descending	Target Online Fix Publication	Description
TIAGABINE HY DROCHLORID E	ASSAY/ *Procedure*	*USP43–NF38*	4365	20-Nov-2020	1-Dec-2020	*NA*	*NA*	In the *Standard solution*: Change Transfer suitable volumes of the *Standard stock solution* and *Internal standard solution* into a suitable volumetric flask and dilute with *Diluent* to volume. to: 0.1 mg/mL of USP Tiagabine Hydrochloride RS and 0.04 mg/mL of butylparaben in *Diluent* prepared as follows. Transfer suitable volumes of the *Standard stock*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication Sort descending	Target Online Fix Publication	Description
								solution and *Internal standard solution* into a suitable volumetric flask and dilute with *Diluent* to volume. AND In the *Sample solution*: Change Transfer suitable volumes of the *Sample stock solution* and *Internal standard solution* into a suitable volumetric flask and dilute with *Diluent* to volume. to: 0.1 mg/mL of Tiagabine Hydrochloride

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication Sort descending	Target Online Fix Publication	Description
								and 0.04 mg/mL of butylparaben in *Diluent* prepared as follows. Transfer suitable volumes of the *Sample stock solution* and *Internal standard solution* into a suitable volumetric flask and dilute with *Diluent* to volume.
AMLODIPINE AND OLMESARTAN MEDOXOMIL TABLETS	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP43–NF38*	Online	26-Feb-2021	1-Mar-2021	*NA*	*NA*	In USP Amlodipine Related Compound A RS: Change 522.93 to: 522.94
ZIPRASIDONE HYDROCHLORIDE	ADDITIONAL REQUIREMENTS/*USP Reference*	*USP43–NF38*	4699	30-Jul-2021	1-Aug-2021	*NA*	*NA*	In USP Ziprasidone Related Compound F

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication Sort descending	Target Online Fix Publication	Description
	Standards <11>							RS: Change 2-(2-Amino-5-{2-[4-(benzo[*d*]isothiazol-3-yl)piperazin-1-yl]ethyl}-4-chlorophenyl)acetic acid. $C_{21}H_{23}ClN_4O_2S$ 430.95 to: Sodium 2-(2-amino-5-{2-[4-(benzisothiazol-3-yl)piperazin-1-yl]ethyl}-4-chlorophenyl)acetate monohydrate; Also known as Sodium 2-(2-amino-5-{2-[4-(benzo[*d*]isothiazol-3-yl)piperazin-1-yl]ethyl}-4-chlorophenyl)acetate monohydrate. $C_{21}H_{22}ClN_4NaO_2S \cdot H_2O$ 470.95

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication Sort descending	Target Online Fix Publication	Description
ONDANSETRON ORALLY DISINTEGRATING TABLETS	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USPNF Online*	Online	28-Jan-2022	1-Feb-2022	*NA*	*NA*	In USP Ondansetron Related Compound A RS: Change 3-[(Dimethylamino)methyl]-1,2,3,9-tetrahydro-9-methyl-4*H*-carbazol-4-one hydrochloride. $C_{16}H_{20}N_2O \cdot HCl$ 292.80 to: 3-[(Dimethylamino)methyl]-9-methyl-1,2,3,9-tetrahydro-4*H*-carbazol-4-one hydrochloride. $C_{16}H_{20}N_2O \cdot HCl$ 292.81 AND In USP Ondansetron Related Compound D RS: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication Sort descending	Target Online Fix Publication	Description
								1,2,3,9-Tetrahydro-9-methyl-3-methylene-4*H*-carbazol-4-one. to: 9-Methyl-3-methylene-1,2,3,9-tetrahydro-4*H*-carbazol-4-one.
AMMONIUM GLYCYRRHIZATE	CHEMICAL INFORMATION	*USPNF Online*	Online	24-Jun-2022	1-Jul-2022	*NA*	*NA*	Change 840.08 to: 839.97
SUTURES--NEEDLE ATTACHMENT	PROCEDURE	*USPNF Online*	Online	29-Jul-2022	1-Aug-2022	*NA*	*NA*	In *Removable Needle Attachment*: Change For USP sizes 5-0 through 2-0, to: For USP sizes 5-0 through 2,
METACRESOL	IDENTIFICATION/*B.*	*USP41–NF36*	2605	28-Dec-2018	1-Jan-2019	*NA*	*NA*	Change The retention time of the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication Sort descending	Target Online Fix Publication	Description
								major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the *Assay*. to: The retention time of the metacresol peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the *Assay*.
PSEUDOEPHEDRINE HYDROCHLORIDE EXTENDED-RELEASE TABLETS	PERFORMANCE TESTS/ *Dissolution <711>*	*Revision Bulletin (Official March 01, 2019)*	Online	26-Apr-2019	1-May-2019	*NA*	*NA*	In the *Figure 1* caption: Change (see *Drug Release <724>, Figure 4c*) to: (see *Drug Release <724>,*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication Sort descending	Target Online Fix Publication	Description
								Figure 5c)
CHLOROQUINE PHOSPHATE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP42–NF37*	939	30-Aug-2019	1-Sep-2019	*NA*	*NA*	In USP Chloroquine Related Compound G RS: Change $C_{18}H_{26}Cl_3NO \cdot H_2SO_4$ to: $C_{18}H_{26}ClN_3O \cdot H_2SO_4$
DEMECLOCYCLINE HYDROCHLORIDE	SPECIFIC TESTS/*Loss on Drying*	*USP43–NF38*	1248	24-Apr-2020	1-May-2020	*NA*	*NA*	In *Analysis*: Change Dry the *Sample* at 60° for 3 h. to: Dry the *Sample* in a capillary-stoppered bottle in vacuum at 60° for 3 h.
ATROPINE SULFATE	CHEMICAL INFORMATION	*USP43–NF38*	428	26-Jun-2020	1-Jul-2020	*NA*	*NA*	Change 694.83 to: 694.84
NATEGLINIDE	CHEMICAL INFORMATION	*USP43–NF38*	Online	30-Oct-2020	1-Nov-2020	*NA*	*NA*	This erratum applies to the USP-NF ONLINE platform only.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication Sort descending	Target Online Fix Publication	Description
ATORVASTATIN CALCIUM	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP43–NF38*	414	20-Nov-2020	1-Dec-2020	*NA*	*NA*	See http://uspnf.com/nateglinide-err-img-20201030 for correction In USP Atorvastatin Related Compound C RS: Change Difluoro impurity, or (3*R*,5*R*)-7-[3-(phenylcarbamoyl)-4,5-bis(4-fluorophenyl)-2-iso propyl-1*H*-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid, calcium salt. to: Calcium (3*R*,5*R*)-7-[2,3-Bis(4-fluorophenyl)-5-isopropyl-4-(phenylcar

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication Sort descending	Target Online Fix Publication	Description
								bamo yl)-1*H* -pyrrol-1-yl]-3,5-dihydroxyhepta noate (1:2); Also known as Difluoro impurity, or (3*R*,5*R*)-7-[3-(phenylca rbamoyl)-4,5-bis (4-fluorophenyl) -2 -iso propyl-1*H* -pyrrol-1-yl]-3,5-dihydroxyhepta noic acid, calcium salt. AND In USP Atorvastatin Related Compound D RS: Change Epoxide impurity, or 3-(4 -fluorobenzoyl)-2-isobutyryl-3-p henyl-oxirane-2-

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication Sort descending	Target Online Fix Publication	Description
								carboxylic acid phenylamide. to: 3-(4-Fluorobenzoyl)-2-isobutyryl-*N*,3-diphenyloxirane-2-carboxamide; Also known as Epoxide impurity, or 3-(4-fluorobenzoyl)-2-isobutyryl-3-phenyl-oxirane-2-carboxylic acid phenylamide. AND In USP Atorvastatin Related Compound E RS: Change 3*S*,5*S* Enantiomer, or (3*S*,5*S*)-7-[3-(phenylcarbamoyl)-5-(4-fluorophenyl)-2-isopropyl-4-phenyl-1*H*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication Sort descending	Target Online Fix Publication	Description
								-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid, calcium salt. $C_{66}H_{68}CaF_2N_4O_{10}$ 1155.34 to: Calcium (3*S*,5*S*)-7-[2-(4-Fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1*H*-pyrrol-1-yl]-3,5-dihydroxyheptanoate (1:2); Also known as 3*S*,5*S* Enantiomer, or (3*S*,5*S*)-7-[3-(phenylcarbamoyl)-5-(4-fluorophenyl)-2-isopropyl-4-phenyl-1*H*-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid, calcium salt.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication Sort descending	Target Online Fix Publication	Description
								$C_{66}H_{68}CaF_2N_4O_{10}$ 1155.38 AND In USP Atorvastatin Related Compound H RS: Change 540.62 to: 540.64 AND In Atorvastatin Related Compound I RS: Change 654.81 to: 654.82
BIFIDOBACTERIUM LONGUM SUBSP. LONGUM	DEFINITION	*USPNF 2021 ISSUE 1*	Online	28-May-2021	1-Jun-2021	*NA*	*NA*	Change *Bifidobacterium longum* subsp. *longum* comprises to: *Bifidobacterium longum* subsp. *longum* comprises
ISOSORBIDE	*Dissolution*	*USPNF 2021*	Online	19-Nov-2021	1-Dec-2021	*NA*	*NA*	In *Test 2*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication Sort descending	Target Online Fix Publication	Description
DINITRATE EX TENDED-RELEASE TABLETS	*<711>*	*ISSUE 1*						Change Determine the amount of isosorbide dinitrate ($C_6H_9NO_6$) dissolved by employing the following method. to: Determine the amount of isosorbide dinitrate ($C_6H_8N_2O_8$) dissolved by employing the following method.
APREPITANT CAPSULES	PERFORMANCE TESTS/ *Dissolution <711>*	*USPNF Online*	Online	27-May-2022	1-Jun-2022	*NA*	*NA*	Change **Test 1** Dilute 1 mL of phosphoric acid with water to 1 L. to: **Test 1** AND

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication Sort descending	Target Online Fix Publication	Description
								Change **Dilute phosphoric acid:** to: **Dilute phosphoric acid:** Dilute 1 mL of phosphoric acid with water to 1 L.
ANALYTICAL DATA—INTERPRETATION AND TREATMENT	MEASUREMENT PRINCIPLES AND VARIATION	*USP42–NF37*	7129	22-Feb-2019	1-Mar-2019	*NA*	*NA*	See https://www.usp nf.com/sites/def ault/files/usp_pd f/EN/february_2 019_errata_ima ge1.pdf for correction
ROSUVASTATIN TABLETS	PERFORMANCE TESTS/ *Dissolution <711>/Test 3*	*Revision Bulletin (Official April 01, 2019)*	Online	31-May-2019	1-Jun-2019	*NA*	*NA*	In *Medium*: Change (dissolve 63.0 of citric acid to: (dissolve 63.0 g of citric acid
MEFENAMIC ACID	PERFORMANCE	*USP42–NF37*	2711	22-Nov-2019	1-Dec-2019	*NA*	*NA*	Change *Solution A*,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication Sort descending	Target Online Fix Publication	Description
CAPSULES	TESTS/ *Dissolution* <711>							*Mobile phase*, *Standard solution*, *Sample solution*, *Chromatographic system*, and *System suitability*: Proceed as directed in the *Assay*, making any necessary volumetric adjustments. to: *Solution A*, *Mobile phase*, *Standard solution*, *Chromatographic system*, and *System suitability*: Proceed as directed in the *Assay*, making any necessary volumetric adjustments.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication Sort descending	Target Online Fix Publication	Description
								Sample solution: Take a portion of the solution under test, and dilute if necessary.
WATER-SOLUBLE VITAMINS WITH MINERALS TABLETS	STRENGTH	*USP43–NF38*	5552	24-Apr-2020	1-May-2020	*NA*	*NA*	In the Calculate statement in *Niacin or Niacinamide, Pyridoxine Hydrochloride, Riboflavin, and Thiamine, Method 1/Analysis*: Delete , calcium pantothenate ($C_{18}H_{32}CaN_2O_{10}$), and folic acid ($C_{19}H_{19}N_7O_6$), AND In the Calculate statement in *Niacin or Niacinamide, Pyridoxine Hydrochloride,*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication Sort descending	Target Online Fix Publication	Description
DALFAMPRIDI	IDENTIFICATIO	*USP43–NF38*	1228	25-Sep-2020	1-Oct-2020	*NA*	*NA*	*Riboflavin, and Thiamine, Method 3/Analysis*: Delete , calcium pantothenate ($C_{18}H_{32}CaN_2O_{10}$), and folic acid ($C_{19}H_{19}N_7O_6$), AND In the Calculate statement in *Folic Acid, Method 3; Ascorbic Acid, Niacin or Niacinamide, Pyridoxine Hydrochloride, Calcium Pantothenate, Riboflavin, and Thiamine, Method 4/Analysis*: Add ascorbic acid ($C_6H_8O_6$), Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication Sort descending	Target Online Fix Publication	Description
NE	N/*A*.							*Infrared Absorption* ?197?: [Note—Methods described in ?197K? or ?197A? may be used.] to: *Spectroscopic Identification Tests* ?197?, *Infrared Spectroscopy*: 197K or 197A
GLYBURIDE AND METFORMIN HYDROCHLORIDE TABLETS	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP43–NF38*	2128	26-Mar-2021	1-Apr-2021	*NA*	*NA*	In USP Glyburide Related Compound A RS: Change 368.84 to: 368.83
?643? TOTAL ORGANIC CARBON	PROCEDURES	*USPNF 2021 ISSUE 1*	Online	27-Aug-2021	1-Sep-2021	*NA*	*NA*	In *1. Bulk Water/1.10 System suitability*: Change r_E = 100 × [(*r*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication Sort descending	Target Online Fix Publication	Description
								$_C/r_L$) to: $r_E = 100 \times (r_C/r_L)$
PROPYLENE GLYCOL DIACETATE	IMPURITIES/*Organic Impurities*	*USPNF Online*	Online	25-Feb-2022	1-Mar-2022	*NA*	*NA*	In *Analysis*: Change r_S = sum of all the peak areas, excluding the solvent peaks from the *Standard solution* to: r_S = sum of all the peak areas, excluding the solvent peaks from the *Sample solution*
AZITHROMYCIN FOR ORAL SUSPENSION	ASSAY/ *Procedure*	*USPNF 2021 ISSUE 1*	Online	30-Apr-2021	1-May-2021	*NA*	*NA*	In *Solution A*: Change orthophosphoric acid to: phosphoric acid
ANALYTICAL METHODOLOGIES BASED ON SCATTERING PHENOMENA-	2. INTRODUCTION	*USPNF 2021 ISSUE 1*	Online	24-Sep-2021	1-Oct-2021	*NA*	*NA*	In paragraph five: Change *Determination of Zeta Potential by*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication Sort descending	Target Online Fix Publication	Description
GENERAL								*Electrophoretic Light Scattering* ?432?[1] to: *Determination of Zeta Potential by Electrophoretic Light Scattering* ?432? AND In footnote 1: Change This chapter will appear in a future *Pharmacopeial Forum* (*PF*) issue. to: This chapter appeared in issue 46(3) of the *Pharmacopeial Forum* (*PF*).
ONDANSETRON TABLETS	ADDITIONAL REQUIREMENTS/*USP Reference*	*USPNF Online*	Online	25-Mar-2022	1-Apr-2022	*NA*	*NA*	Change USP Ondansetron Related

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication Sort descending	Target Online Fix Publication	Description
	Standards <11>							Compound A RS 3-[(Dimethylamino)methyl]-1,2,3,9-tetrahydro-9-methyl-4*H*-carbazol-4-one hydrochloride. to: USP Ondansetron Related Compound A RS 3-[(Dimethylamino)methyl]-9-methyl-1,2,3,9-tetrahydro-4*H*-carbazol-4-one hydrochloride.
SALIX SPECIES BARK	ADDITIONAL REQUIREMENTS	*USP42–NF37*	5185	25-Jan-2019	1-Feb-2019	*NA*	*NA*	In *Labeling*: Change The label states the Latin binomial(s) of one or several *Salix* species included in the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication Sort descending	Target Online Fix Publication	Description
								article. to: The label states the Latin binomial(s) of one or several *Salix* species included in the article. Dosage forms prepared with this article should bear the following statement: Not for use in children, women who are pregnant or nursing, or by persons with known sensitivity to aspirin. AND In *USP Reference Standards* <*11*>: Delete (This monograph is

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication Sort descending	Target Online Fix Publication	Description
								postponed indefinitely.)
DRONEDARONE TABLETS	PERFORMANCE TESTS/ *Dissolution <711>*	*USP42–NF37*	1519	31-May-2019	1-Jun-2019	*NA*	*NA*	In *Tolerances*/*30 min*: Change 20.0%–60.0% (*Q*) of the labeled amount of dronedarone free base to: 20.0%–60.0% of the labeled amount of dronedarone free base
MORPHINE SULFATE EXTENDED-RELEASE CAPSULES	IMPURITIES/*Organic Impurities*	*USP42–NF37*	Online	30-Aug-2019	1-Sep-2019	*NA*	*NA*	Change *Diluent*, *Solution A*, *System suitability solution*, *Chromatographic system*, and *Sample solution*: Proceed as directed in the *Assay*. to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication Sort descending	Target Online Fix Publication	Description
								Diluent, *Buffer solution*, *Solution A*, *Solution B*, *Mobile phase*, *System suitability solution*, *Chromatographic system*, and *Sample solution*: Proceed as directed in the *Assay*.
NIACIN	IDENTIFICATION/*B.*	*USP43–NF38*	3138	24-Apr-2020	1-May-2020	*NA*	*NA*	Change *Ultraviolet Absorption* <197U> to: *Spectroscopic Identification Tests* <197>, *Ultraviolet-Visible Spectroscopy*: 197U
ETHAMBUTOL HYDROCHLORIDE	IMPURITIES/*Limit of Aminobutanol*	*USP43–NF38*	1762	31-Jul-2020	1-Aug-2020	*NA*	*NA*	In *Acceptance criteria*: Change The

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication Sort descending	Target Online Fix Publication	Description
								fluorescence intensity of the solution from the *Sample solution* is NMT 1.0% of the difference between the intensities of the two solutions. to: The fluorescence intensity of the solution from the *Sample solution* is NMT the difference between the intensities of the two solutions (NMT 1.0%).
THE DISSOLUTION PROCEDURE: DEVELOPMENT AND VALIDATION	2. METHOD DEVELOPMENT	*Second Supplement to USP43–NF38*	Online	20-Nov-2020	1-Dec-2020	*NA*	*NA*	In paragraph 2 of *2.4 Study Design*/*2.4.1 Time Points*: Change *Assessment of Drug Product P*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication Sort descending	Target Online Fix Publication	Description
								erformance—Bio availability, Bioequivalence, and Dissolution ?1090?. to: *Assessment of Solid Oral Drug Product Performance and Interchange ability, Bioavailability, Bioequivalence, and Dissolution* ?1090?.
RISKS AND MITIGATION STRATEGIES FOR THE STORAGE AND TRANSPORTATION OF FINISHED DRUG PRODUCTS	4. RISK MITIGATION CATEGORIES AS QMS ELEMENTS	*Second Supplement to USP43–NF38*	Online	29-Jan-2021	1-Feb-2021	*NA*	*NA*	In *4.1 Documentation and Proc edures/4.1.3 Labels*: Change The use of symbols that are recognized by international organizations is strongly recommended. to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication Sort descending	Target Online Fix Publication	Description
								The use of symbols that are recognized by international organizations is strongly recommended. See *General Notices, 10.20. Labeling*.
BENAZEPRIL HYDROCHLORIDE TABLETS	ADDITIONAL REQUIREMENTS/*USP References Standards <11>*	*USP43–NF38*	Online	25-Jun-2021	1-Jul-2021	*NA*	*NA*	In USP Benazepril Related Compound B RS: Change (3*S*)-3-[[(1*R*)-1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-2,3,4,5-tetrahydro-2-oxo-1*H*-1-benzazepine-1-acetic acid, monohydrochloride; Also known as 2-[(*SR*)-3-{[(*RS*)-1-Ethoxy-1-ox

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication Sort descending	Target Online Fix Publication	Description
								o-4-phenylbutan-2-yl]amino}-2-oxo-2,3,4,5-tetrahydro-1*H*-benzo[*b*]azepin-1-yl]acetic acid hydrochloride. to: 2-[(*S*)-3-{[(*R*)-1-Ethoxy-1-oxo-4-phenylbutan-2-yl]amino}-2-oxo-2,3,4,5-tetrahydro-1*H*-benzo[*b*]azepin-1-yl]acetic acid hydrochloride; Also known as (3*S*)-3-[[(1*R*)-1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-2,3,4,5-tetrahydro-2-oxo-1*H*-1-benzazepine-1-acetic acid, monohydrochlorid

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication Sort descending	Target Online Fix Publication	Description
EXTENDED PHENYTOIN SODIUM CAPSULES	IMPURITIES/*Organic Impurities*	*Revision Bulletin (Official March 01, 2021)*	Online	31-Dec-2021	1-Jan-2022	*NA*	*NA*	e. In both Calculations in *Analysis*: Change C_U = nominal concentration of phenytoin in the *Sample solution* (µg/mL) to: C_U = nominal concentration of phenytoin sodium in the *Sample solution* (µg/mL)
DOXYCYCLINE FOR INJECTION	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USPNF Online*	Online	24-Jun-2022	1-Jul-2022	*NA*	*NA*	In USP Doxycycline Related Compound A RS: Change 444.43 to: 444.44 AND Change (4*S*,4a*R*,5*S*,5a*R*,6*S*,12a*S*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication Sort descending	Target Online Fix Publication	Description
								)-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide, monohydrochloride. $C_{22}H_{24}N_2O_8$ · HCl 480.13 to: (4*S*,4a*R*,5*S*,5a*R*,6*S*,12a*S*)-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide hydrochloride. $C_{22}H_{24}N_2O_8$ · HCl 480.90
CLONIDINE TRANSDERMAL	PERFORMANCE TESTS/*Drug*	*USP42–NF37*	1084	26-Apr-2019	1-May-2019	*NA*	*NA*	*Apparatus 7*: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication Sort descending	Target Online Fix Publication	Description
SYSTEM	*Release <724>/Test 1*							(see *Figure 4a*). to: (see *Figure 5a*).
CHITOSAN	ASSAY/*Degree of Deacetylation*	*USP42–NF37*	5663	28-Jun-2019	1-Jul-2019	*NA*	*NA*	In the *Analysis*: Change Result = {1 ? [(7 × A_2)/(3 × A_1)] × 100 to: Result = {1 ? [(7 × A_2)/(3 × A_1)]} × 100
SODIUM BICARBONATE	IM PURITIES/*Carbonate/Analysis*	*USP42–NF37*	Online	22-Nov-2019	1-Dec-2019	*NA*	*NA*	Remove the external reference to a reagent in Sodium Bicarbonate
NUCLEIC ACID-BASED TECHNIQUES -- GENERAL	APPENDICES	*USP43–NF38*	7865	24-Apr-2020	1-May-2020	*NA*	*NA*	In *Appendix 2*: Delete the Row for dNTP dinucleotide triphosphate
AMLODIPINE BESYLATE TABLETS	IDENTIFICATION/*A.*	*USP43–NF38*	286	25-Sep-2020	1-Oct-2020	*NA*	*NA*	Change *Spectroscopic Identification Tests* ?197?, *Ultraviolet Spectroscopy*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication Sort descending	Target Online Fix Publication	Description
								197U to: *Spectroscopic Identification Tests* ?197?, *Ultraviolet-Visible Spectroscopy*: 197U
THALIDOMIDE	*Assay*	*USP42–NF37*	4281	26-Apr-2019	1-May-2019	*NA*	*NA*	In *Chromatographic system*: Change and the relative standard deviation for replicate injections is not more than 1.0%. to: and the relative standard deviation for the response ratio of thalidomide to phenacetin is not more than 1.0%.
GLUCAGON		*USP42–NF37*	6478	26-Jul-2019	1-Aug-2019	*NA*	*NA*	In *Standard*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication Sort descending	Target Online Fix Publication	Description
BIOIDENTITY TESTS	*B. In Vitro Cell-Based Bioidentity Test*							*stock solution*: Change 0.4 µg/mL to: 4 µg/mL
CALCIUM ACETATE CAPSULES	PERFORMANCE TESTS/ *Dissolution <711>*	*Revision Bulletin (Official January 01, 2020)*	Online	28-Feb-2020	1-Mar-2020	*NA*	*NA*	In *Test 1/Analysis*: Change dissolved at time point (*i*): $Result_i = (r_U/r_S) \times C_S \times V \times D \times (1/L) \times 100$ to: dissolved: $Result = (r_U/r_S) \times C_S \times V \times D \times (1/L) \times 100$ AND In *Test 3/Analytical procedure 1/Analysis*: Change *V* = volume of *Medium*, 900 mL to: *V* = volume of *Medium 1*, 900

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication Sort descending	Target Online Fix Publication	Description
								mL AND In *Test 3*/*Analytical procedure 2*/*Analysis*: Change V_M = volume of *Medium*, 900 mL to: V_M = volume of *Medium 1*, 900 mL AND In *Test 3*/*Analytical procedure 3*/*Blank*: Change *Medium* to: *Medium 2* AND In *Test 3*/*Analytical procedure 3*/*Analysis*: Change *V*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication Sort descending	Target Online Fix Publication	Description
FILGRASTIM	IM PUR ITIES/*Organic Impurities*	*USP43–NF38*	Online	29-May-2020	1-Jun-2020	*NA*	*NA*	$_M$= volume of *Medium*, 900 mL to: V_M = volume of *Medium 2*, 900 mL In *Related Co mpoun ds*/*Standard solution*: Change 0.75 mg/mL of in water to: 0.75 mg/mL of USP Filgrastim RS in water AND In *Impurities with Charges Different from Filgra stim*/*Reference solution A*: Change 1 mg/mL of in water to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication Sort descending	Target Online Fix Publication	Description
								1 mg/mL of USP Filgrastim RS in water AND In *Impurities with Charges Different from Filgrastim/Reference solution B*: Change Dilute *Reference solution A* with water to obtain a concentration of 20 µg/mL of . to: Dilute *Reference solution A* with water to obtain a concentration of 20 µg/mL of USP Filgrastim RS. AND In *Impurities with Charges Different from*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication Sort descending	Target Online Fix Publication	Description
								Filgra stim/*Reference solution C*: Change 3 mg/mL of in water to: 3 mg/mL of USP Filgrastim RS in water AND In *Impurities with Molecular Weight Different from That of Filgra stim*/*Reference solution A*: Change Dilute 25 µg of with 25 µL of *4X SDS sample buffer* and sufficient water to obtain 100 µL of a solution containing a 250-µg/mL preparation of in 1X SDS sample

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication Sort descending	Target Online Fix Publication	Description
								buffer. to: Dilute 25 µg of USP Filgrastim RS with 25 µL of *4X SDS sample buffer* and sufficient water to obtain 100 µL of a solution containing a 250-µg/mL preparation of USP Filgrastim RS in 1X SDS sample buffer. AND In *Impurities with Molecular Weight Different from That of Filgra stim/Reference solution B*: Change Prepare both a reduced and a nonreduced *Reference*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication Sort descending	Target Online Fix Publication	Description
								solution B by diluting *Reference solution A* (1:100) with the appropriate 1X SDS sample buffer to obtain a 2.5-µg/mL preparation of . to: Prepare both a reduced and a nonreduced *Reference solution B* by diluting *Reference solution A* (1:100) with the appropriate 1X SDS sample buffer to obtain a 2.5-µg/mL preparation of USP Filgrastim RS. AND In *Impurities with Molecular*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication Sort descending	Target Online Fix Publication	Description
								Weight Different from That of Filgra stim/Reference solution C: Change Dilute 75 µg of with 25 µL of *4X SDS sample buffer* and sufficient water to obtain 100 µL of a solution containing a 750-µg/mL preparation of in 1X SDS sample buffer. to: Dilute 75 µg of USP Filgrastim RS with 25 µL of *4X SDS sample buffer* and sufficient water to obtain 100 µL of a solution containing a 750-µg/mL

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication Sort descending	Target Online Fix Publication	Description
								preparation of USP Filgrastim RS in 1X SDS sample buffer. AND In *Limit of High Molecular Weight Proteins /Resolution solution*: Change Dissolve about 1 mg of in 0.33 mL of 0.25 M sucrose, to: Dissolve about 1 mg of USP Filgrastim RS in 0.33 mL of 0.25 M sucrose, AND In *Limit of High Molecular Weight Proteins /Standard solution*: Change 0.3 mg/mL of in water

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication Sort descending	Target Online Fix Publication	Description
								to: 0.3 mg/mL of USP Filgrastim RS in water
CLOMIPHENE CITRATE TABLETS	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*First Supplement to USP43–NF38*	Online	30-Oct-2020	1-Nov-2020	*NA*	*NA*	In USP Clomiphene Related Compound A RS: Change (*E,Z*)-2-[4-(1,2-Diphenylethyl)phenoxy]-*N,N*-diethylethanamine hydrochloride. to: (*E,Z*)-2-[4-(1,2-Diphenylethenyl)phenoxy]-*N,N*-diethylethanamine hydrochloride.
CARBOMER COPOLYMER	IMPURITIES	*USPNF 2021 ISSUE 1*	Online	28-May-2021	1-Jun-2021	*NA*	*NA*	In *Limit of Ethyl Acetate and Cyclohexane/Analysis*: Change *Samples: Standard stock*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication Sort descending	Target Online Fix Publication	Description
								solution, Standard solution A, Standard solution B, Standard solution C, and *Sample solution* to: *Samples: Standard solution A, Standard solution B, Standard solution C,* and *Sample solution* AND In *Limit of Benzene/Analysis*: Change *Samples*: *Standard stock solution, Standard solution A, Standard solution B, Standard solution C,* and

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication Sort descending	Target Online Fix Publication	Description
DOXAZOSIN MESYLATE	IM PURITIES/*Organic Impurities*	*USPNF 2021 ISSUE 1*	Online	29-Oct-2021	1-Nov-2021	*NA*	*NA*	*Sample solution* to: *Samples: Standard solution A, Standard solution B, Standard solution C,* and *Sample solution* In *Table 2*: Change Doxazosin related compound D[g] 0.83, 196.16, 196.16, 0.25 to: Doxazosin related compound D[g] 0.83, 180.16, 180.16, 0.25
MUPIROCIN CALCIUM	CHEMICAL INFORMATION	*USPNF Online*	Online	29-Apr-2022	1-May-2022	*NA*	*NA*	Change 1075.34 to: 1075.35

Pagination

- First page « First
- Previous page ‹ Previous
- Page 1
- Current page 2
- Page 3
- Page 4
- Page 5
- Page 6
- Page 7
- Page 8
- Page 9
- …
- Next page Next ›
- Last page Last »